Earnings Call: Smith & Nephew Sees Mixed Growth Despite Challenges in China

image

Earnings Call: Smith & Nephew Sees Mixed Growth Despite Challenges in China

Global medical technology company Smith & Nephew (NYSE:SNN) reported a 4% core revenue growth in its third-quarter trading update, achieving revenue of $1.4 billion. CEO Deepak Nath expressed optimism about progress in the U.S. market while acknowledging that challenges in China have led to a downward revision of full-year growth expectations.

Key Highlights:

  • Smith & Nephew reported total revenues of $1.4 billion with a 4% core revenue growth.
  • Reconstruction growth in the U.S. improved due to operational enhancements, contributing positively to results.
  • Performance in surgical areas in China weakened and impacted overall growth.
  • The full-year growth forecast was lowered from the previous 5% to 6% range to approximately 4.5%.
  • A trade margin expansion of up to 50 basis points is expected, with a long-term target of 19% to 20% by 2025.
  • Innovative product launches contributed nearly half of the total revenue growth in 2023.
  • Smith & Nephew remains cautious about the China market, with a recovery anticipated in 2025.
  • The full-year growth projection was lowered to approximately 4.5% due to weaker performance in the outlook.
  • The margin outlook for the year was adjusted to account for a potential increase of up to 50 basis points.
  • Revenue growth for 2024-2025 is expected to be around 5%, with a target gross margin of 20% by 2025.

Declining Indicators:

  • China has shifted from being a neutral contributor to nearly a 2 percentage point drag.
  • Concerns about loss of market share in China due to local competition and lower-than-expected volume growth.
  • A slight increase in input cost inflation has been observed, affecting margin expectations.

Rising Indicators:

  • Growth outside China was strong, at 5.9% in Q3 and 5.1% year-to-date.
  • Operational improvements in the U.S. are expected to enhance market participation.
  • The trauma franchise is showing double-digit growth, aided by the impact of the EVOS system.

Missed Points:

  • The full-year growth forecast and margin expectations for 2024 and 2025 have been downgraded primarily due to the China market.
  • Particularly uneven supply recovery for knee products in the OXINIUM line in key markets.

Q&A Highlights:

  • Management remains confident in the 12-Point Plan, expecting significant margin expansion by 2025.
  • Visibility over distributor inventories in China shows ongoing stock depletion into Q4 and the first half of 2025.
  • The U.S. knee business is expected to return to growth in the second half of 2025, while the hip segment continues to grow at a steady rate.

Despite challenges faced in China, CEO Deepak Nath stated that the company is committed to its strategic initiatives, including the 12-Point Plan. The focus on operational improvements and efficiency gains is expected to sustain growth and enhance margins. With a cautious outlook for China, Smith & Nephew is laying the groundwork for long-term success while managing current challenges.

InvestingPro Insights: Smith & Nephew's recent financial performance and market position are further illuminated by data from InvestingPro. Despite challenges in China and downward revisions in growth expectations, the company maintains a solid financial foundation.

According to InvestingPro data, Smith & Nephew's market capitalization stands at $10.9 billion, reflecting its significant presence in the medical technology sector. The company's revenue for the last twelve months as of Q2 2024 was $5.642 billion, recording a revenue growth of 5.48% for the same period. This aligns with the 4% core revenue growth reported in Q3 and supports management's adjusted full-year growth forecast of approximately 4.5%.

InvestingPro highlights that Smith & Nephew has sustained uninterrupted dividend payments for 48 years, demonstrating its commitment to shareholder returns even during challenging times. This is particularly noteworthy given the current dividend yield of 2.16%, which may attract income-focused investors.

The company's financial health is further underscored by its liquid assets exceeding short-term obligations, providing a buffer against market fluctuations and operational challenges like those experienced in China.

It is essential to note that Smith & Nephew has been trading near its 52-week low, with a 1-month price total return of -15.44%. This may present a potential opportunity for investors who believe in the company's long-term strategy and ability to overcome current challenges.

For readers seeking a deeper dive into Smith & Nephew's financials and market position, InvestingPro offers 12 additional insights that provide a comprehensive overview of the company's expectations and challenges.